Results 131 to 140 of about 215,870 (306)

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono   +10 more
wiley   +1 more source

Building a Robust Investigator‐Initiated Platform: The I‐CARE Experience

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Investigator‐initiated studies that include information collected by patients are rising, but limited data is available on patient and investigator experience in this setting. The I‐CARE cohort included patients with inflammatory bowel disease (IBD) monthly collecting clinical information in 15 countries for up to 6 years.
Julien Kirchgesner   +906 more
wiley   +1 more source

Exploring the health benefits of gut microbiota metabolites on combating ulcerative colitis via network pharmacology, bioinformatics and molecular docking

open access: yesScientific Reports
Ulcerative colitis (UC) is a leading health challenge worldwide. The evidence of the benefits of gut microbiota metabolites for the treatment of ulcerative colitis is accumulating, but the underlying mechanism remains to be further elucidated. Hence, the
Weiguo Yao   +3 more
doaj   +1 more source

β-ionone prevents dextran sulfate sodium-induced ulcerative colitis and modulates gut microbiota in mice

open access: yesFood Innovation and Advances
β-ionone has various biological activities, such as anti-inflammatory, antimicrobial, and anticancer effects. The pathogenesis of ulcerative colitis is correlated with immune dysfunction, intestinal barrier damage, and gut microbiota imbalance.
Jingjing Fang   +5 more
doaj   +1 more source

Ulcerative colitis: let's talk about extent [PDF]

open access: yes, 2016
Ulcerative colitis (UC) is a chronic inflammatory disease in which clinical course varies substantially between patients. The extent of the disease is usually pointed out as one of the factors responsible for this variation.
Antunes, A.   +7 more
core  

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi   +100 more
wiley   +1 more source

Fibroblast Plasticity in Inflammation of the Barrier

open access: yesBarrier Immunity, EarlyView.
Under inflammatory condition, fibroblasts in barrier tissues integrate inflammatory, senescent, and mechanical inputs. These pathways activate central signaling networks to drive fibroblast phenotypic transition, enabling cytokine production, immune cell recruitment, and extracellular matrix remodeling.
Chen Zhang, Hao Wu, Wei Li
wiley   +1 more source

Gut‐microbiota‐brain Axis and post‐traumatic epilepsy

open access: yesEpilepsia Open, EarlyView.
Abstract There has been growing evidence that perturbations in gut‐microbiota‐brain axis (GMBA) are involved in mechanisms of chronic sequelae of traumatic brain injury (TBI). This review discusses the connection between GMBA and post‐traumatic epilepsy (PTE), the latter being a common outcome of TBI.
Andrey Mazarati
wiley   +1 more source

Signifiance of autoimmune reactions to pancreatic juice in Crohn´s disease [PDF]

open access: yes, 1988
Goebell, Harald   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy